Research Highlights Surgical Management Disparities in American Indian and Native Alaskans With Breast Cancer

Article

Findings from a study indicated that non-Hispanic American Indian and Alaskan Native patients with breast cancer were more likely to undergo a mastectomy compared with non-Hispanic White patients.

Non-Hispanic American Indian and Alaskan Native patients undergo a higher percentage of mastectomy compared with non-Hispanic White patients, highlighting disparities in surgical management, as well as a need to drive awareness about these issues, decision making, and access to breast conservation for this patient population, according to a study published in Annals of Surgical Oncology.

For early-stage breast cancer, non-Hispanic American Indian or Alaskan Native patients had a significantly higher higher rate of mastectomies at 41% compared with non-Hispanic White patients at 34.4% (P <.001). Additionally, non-Hispanic American Indian and Alaskan Native individuals had a lower lumpectomy rate of 59% compared with 65.6% in non-Hispanic white individuals. However, investigators stated that no significant differences in post–lumpectomy radiation (71% vs 70%) were observed in either group, respectively.

“Disparities in breast cancer screening, stage, and morbidity or mortality have been examined previously for non-Hispanic American Indian and Alaskan Native women compared with the general population; however, we believe this is the first study to specifically examine disparities in breast cancer surgery for non-Hispanic American Indian and Alaskan Native women,” the investigators wrote.

Between the years of 2010 and 2015, 3292 non-Hispanic American Indian and Alaskan Native women and 165,225 non-Hispanic White women diagnosed with breast cancer were identified. A total of 94% non-Hispanic American Indian and Alaskan Native and 95.7% non-Hispanic White patients who underwent a lumpectomy had early-stage disease. The rates of post–lumpectomy radiation for non-Hispanic American Indian and Alaskan Native individuals was 68.9% and 68.3% for non-Hispanic White individuals.

When combining all sates and regions, non-Hispanic American Indian and Alaskan Native patients had a lower incidence of breast cancer compared with non-Hispanic White women (risk ratio, 0.90; 95% CI, 0.87-0.93). Patients from Alaska (RR, 1.33; 95% CI, 1.18-1.50) and those from the Southern Plains (RR, 1.28; 95% CI, 1.20-1.38) had a significantly higher incidence than those from the Pacific Coast (RR, 0.89; 95% CI, 0.83-0.96), the East (RR, 0.63; 95% CI, 0.54-0.67), and the Southwest (RR, 0.57; 95% CI, 0.51-0.62).

During early-stage disease, incidence was significantly lower for non-Hispanic American Indian and Alaskan Native patients compared with non-Hispanic White patients in all regions (RR, 0.86; 95% CI, 0.83-0.90). Additional findings from the study indicated that non-Hispanic American Indian and Alaskan Native individuals had a higher incidence of late-stage disease in all regions combined (RR, 1.08; 95% CI, 1.01-1.17).

Of the non-Hispanic American Indian and Alaskan Native patients in the Northern Plains, 48.9% underwent mastectomy for early-stage disease compared with 35.9% for non-Hispanic White women (P <.001). For those in Alaska, 47% of the non-Hispanic American Indian and Alaskan Native population received a mastectomy compared with 33.3% of non-Hispanic White women (P <.001).

When examining treatment by region, a higher number of non-Hispanic American Indian and Alaskan Native patients with early-stage breast cancer received post–lumpectomy radiation vs non-Hispanic White patients in the Northern Plains (84.3% vs 77.5%; P = .04), Alaska (71.4% vs 59.9%; P = .03), and Southwest (55.4% vs 43.6%; P = .004).

From 2005 to 2010, non-Hispanic White patients had increased mastectomies, with a decrease noted from 2010 to 2015. Non-Hispanic American Indian and Alaskan Native patients had a an APC of 1.3 for early-stage disease, which increased from 2005 to 2010, plateaued from 2010 to 2014, and then increased from 2014 to 2015 in non-Hispanic White patients. In late-stage disease, the APC remained the same for non-Hispanic American Indian and Alaskan Native individuals but increased from 2005 to 2013 before decreasing from 2013 to 2015 for non-Hispanic White patients.

Reference

Erdrich J, Cordova-Marks F, Monetathchi AR, Wu M, White A, Melkonian S. Disparities in breast-conserving therapy for non-Hispanic American Indian/Alaska Native women compared with non-Hispanic White women. Ann Surg Oncol. Published online September 6, 2021. doi:10.1245/s10434-021-10730-7

Related Videos
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
Related Content